Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

NCT04811027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

HNSCC

Interventions

DRUG: eftilagimod alpha
DRUG: pembrolizumab (KEYTRUDA®)

Sponsor

Immutep S.A.S.

Collaborators

[object Object]